

Drug Policy

Policy:	Xarelto (rivaroxaban)	Annual Review Date: 10/19/2023 Last Revised Date: 10/19/2023
----------------	------------------------------	---

OVERVIEW

Xarelto is an oral factor Xa inhibitor anticoagulant indicated for reduction in the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery, for treatment of DVT and PE, for the reduction in the risk of recurrent DVT and PE following initial therapy, peripheral/coronary artery disease and for prophylaxis of venous thromboembolism in acutely ill medical patients. Additionally, Xarelto is indicated in combination with aspirin to reduce the risk of major cardiovascular (CV) events (CV death, myocardial infarction [MI], and stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).

Anticoagulants and Coronavirus Disease 19 (COVID-19)

Several clinical practice guidelines have been published with regard to use of anticoagulant therapy in the management of COVID-19. In a guideline from the American College of Chest Physicians (CHEST) [June 2, 2020], anticoagulant thromboprophylaxis is suggested over no prophylaxis for acutely ill hospitalized patients with COVID-19.⁷ Extended thromboprophylaxis after hospital discharge is not routinely recommended but may be considered for a patient with low bleeding risk, if emerging data on the post-discharge risk of venous thromboembolism (VTE) and bleeding indicate a net benefit of such prophylaxis. Randomized, controlled trials have not been conducted to evaluate the efficacy of various anticoagulants or placebo in COVID-19 patients; however, the guideline notes that most patients with COVID-19 would have been eligible to participate in landmark trials of anticoagulant thromboprophylaxis in acutely ill medical inpatients. According to guidance from the International Society of Thrombosis and Hemostasis (May 27, 2020), extended post-discharge thromboprophylaxis should be considered for all hospitalized patients with COVID-19 who meet high VTE risk criteria.⁸ Xarelto and Bevyxxa (betrixaban capsules) are cited as treatment options for extended-duration thromboprophylaxis. Likewise, guidance from the Anticoagulation Forum (May 21, 2020) states that for a COVID-19 patient in whom post-discharge prophylaxis is deemed reasonable, an adequately studied and/or approved agent such as Bevyxxa or Xarelto is recommended.

POLICY STATEMENT

This policy involves the use of Xarelto. Prior authorization is recommended for pharmacy benefit coverage of Xarelto. Approval is recommended for those who meet the conditions of coverage in the **Criteria and Initial/Extended Approval** for the diagnosis provided. **Conditions Not Recommended for Approval** are listed following the recommended

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

authorization criteria. Requests for uses not listed in this policy will be reviewed for evidence of efficacy and for medical necessity on a case-by-case basis.

All approvals for initial therapy are provided for the initial approval duration noted below; if reauthorization is allowed, a response to therapy is required for continuation of therapy unless otherwise noted below.

Automation: When available, the following ICD-10 codes and corresponding approval durations will be used for automation to allow approval of the requested medication:

1. I48.*; I82.*; I27.82; 1 year
2. Z96.6*; 60 days

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Xarelto is recommended in those who meet the following criteria:

1. **Atrial Fibrillation, Nonvalvular (or Atrial Flutter)**

Criteria. *Approve for 1 year.*

2. **Deep Vein Thrombosis (DVT) in Patients Undergoing Hip or Knee Replacement Surgery, Prophylaxis**

Criteria. *Approve for 60 days.*

3. **Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), Treatment**

Criteria. *Approve for 1 year.*

4. **Coronary Artery Disease**

Criteria. *Approve for 1 year if patient will be taking concomitant aspirin at least 75mg daily*

5. **Peripheral Artery Disease**

Criteria. *Approve for 1 year if patient will be taking concomitant aspirin at least 75mg daily*

6. **Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) to Reduce the Risk of Recurrence**

Criteria. *Approve for 1 year.*

7. **Reduction in Risk of Major Cardiovascular Events** Approve for 1 year if the patient has coronary artery disease or peripheral artery disease;

8. **Venous Thromboembolism in Acutely Ill Medical Patients, Prophylaxis**

Criteria. *Approve for 60 days.*

Note: This includes post-discharge thromboprophylaxis for a patient hospitalized with coronavirus disease 19 (COVID-19).

Initial Approval/ Extended Approval.

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

indication specific, see above.

OTHER USES WITH SUPPORTIVE EVIDENCE

9. Treatment or Prevention of Other Thromboembolic-Related Conditions (e.g., superficial vein thrombosis, splanchnic vein thrombosis, hepatic vein thrombosis, prophylaxis of venous thromboembolism [VTE] in high-risk patients)

Criteria. Approve for 6 months if the patient meets ONE of the following criteria (A, B, or C):

- A. The patient has tried warfarin, fondaparinux injection, or a low molecular weight heparin (LMWH) product (e.g., enoxaparin injection, Fragmin [dalteparin injection]); OR
- B. The patient has tried another direct oral anticoagulant (e.g. Pradaxa, Savaysa, etc.); OR
- C. The patient has been started on Xarelto for the treatment of an acute thromboembolic condition.

Initial Approval/ Extended Approval.

indication specific, see above.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Xarelto have not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval).

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

Documentation Requirements:

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company. Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

REFERENCES

1. Xarelto® tablets [prescribing information]. Titusville, NJ: Janssen; January 2022.
2. rivaroxaban. In: DRUGDEX (online database). Truven Health Analytics; Greenwood Village, CO. Last updated on 08 November 2019. Accessed on 13 November 2019.
3. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the heart rhythm society. *Circulation*. 2014 April 10 [Epub ahead of print]. Available at: <http://circ.ahajournals.org/content/early/2014/04/10/CIR.0000000000000041>. Accessed on April 12, 2019.

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

4. Guyatt GH, Akl EA, Crowther M, et al., for the American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141:7S-47S.
5. Kearon C, Akl EA, Ormelas J, et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. *Chest*. 2016;149(2):315-352.
6. O’Gara PT, Kushner FG, Ascheim DD, et al, American College of Cardiology Foundation/American Heart Association Task Force on Practice guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;127(4):e362-425. Available at: <http://circ.ahajournals.org/content/127/4/e362.full.pdf+html>. Accessed on April 12, 2019.
7. Jneid H, Anderson JL, Wright S, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2012;126:875-910. Available at: <http://circ.ahajournals.org/content/126/7/875.full.pdf+html>. Accessed on April 12, 2019.
8. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease. *J Am Coll Cardiol*. 2017;70(2):252-289. Available at: http://www.onlinejacc.org/content/70/2/252?_ga=2.10591612.937435023.1508531431-483170820.1508531431. Accessed on April 12, 2019.
9. The NCCN Cancer-Associated Venous Thromboembolic Disease Clinical Practice Guidelines in Oncology (Version 2.2018—August 27, 2018). © 2018 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed on April 12, 2019.
10. Lip G, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. *Chest*. 2018 August 22 [Epub ahead of print]. Available at: [https://journal.chestnet.org/article/S0012-3692\(18\)32244-X/pdf](https://journal.chestnet.org/article/S0012-3692(18)32244-X/pdf). Accessed on April 12, 2019.
11. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. *Chest*. 2020 Sep;158(3):1143-1163.
12. Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost*. 2020; 18: 1859– 1865.
13. Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. *J Thromb Thrombolysis*. 2020 Jul;50(1):72-81.